Physician profile
Sonia Abraham
NPI 1881824704
$6,114.74
in general payments reported to CMS, 2019-2025
48 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $477 · 2021: $616 · 2022: $860 · 2023: $945 · 2024: $1,365 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.25 |
| Education | $116.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,213.52 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $510.76 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $421.02 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $387.58 | 2019-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $322.11 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $300.43 | 2019-2025 | Rexulti, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.82 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $254.80 | 2019-2025 | |
| Novo Nordisk INC | $208.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $188.55 | 2019-2024 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $162.58 | 2019-2023 | |
| Vifor Pharma, INC. | $140.52 | 2019-2024 | Veltassa |
| Glaxosmithkline, LLC. | $139.94 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $135.71 | 2019-2025 | Repatha, Krystexxa, Aranesp |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.05 | 2023-2025 | Caplyta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.